Development of PBPK model of molinate and molinate sulfoxide in rats and humans

Andrew Campbell1

  • 1Department of Environmental Toxicology, UC Davis, Davis, CA 95616, USA. arc40@astound.net

Insights

This study developed a physiologically-based pharmacokinetic (PBPK) model to assess testicular toxicity risk from the herbicide molinate. The model, validated in rats, was extrapolated to humans, predicting molinate concentrations in blood and testes.

Area of Science:

  • Environmental toxicology
  • Pharmacokinetics
  • Reproductive toxicology

Background:

  • Molinate is a widely used herbicide in California rice fields.
  • Molinate sulfoxide, a metabolite, is suspected of causing testicular toxicity in rats.
  • Humans produce similar molinate metabolites as rats.

Purpose of the Study:

  • To develop a preliminary physiologically-based pharmacokinetic (PBPK) model for molinate.
  • To validate the PBPK model in rats.
  • To extrapolate the model to humans for reproductive risk assessment.

Main Methods:

  • A seven-compartment PBPK model was constructed for male Sprague-Dawley rats.
  • The model incorporated flow-limited and diffusion-limited rate equations.
  • Model simulations were compared against experimental molinate concentrations from oral and intravenous doses in rats and a human oral dose.

Main Results:

  • The PBPK model accurately predicted molinate blood concentrations in rats across various doses.
  • The model successfully predicted human molinate blood concentrations after a 5.06mg oral dose.
  • Sensitivity analysis identified key parameters influencing molinate and molinate sulfoxide concentrations.

Conclusions:

  • The PBPK model provides a valuable tool for assessing molinate's reproductive risk.
  • Extrapolation to humans suggests potential for molinate exposure assessment.
  • Key factors influencing testicular exposure to molinate sulfoxide were identified.

Related Concept Videos

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion, mediated...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems01:19

Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems

Phase I biotransformation reactions are integral to drug metabolism, predominantly involving oxidative, reductive, and hydrolytic transformations. Chief among these are oxidative reactions, which enhance the hydrophilicity of xenobiotics and introduce polar functional groups to facilitate their elimination from the body.
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...